



9-2018

# Preliminary Investigation Into the Effect of ACTN3 and ACE Polymorphisms on Muscle and Performance Characteristics

John P. Wagle

*East Tennessee State University*

Kevin M. Carroll

*East Tennessee State University*

Aaron J. Cunanan

*East Tennessee State University*

Alexander Wetmore

*East Tennessee State University*

Christopher Taber

*Sacred Heart University*, [taberc@sacredheart.edu](mailto:taberc@sacredheart.edu)

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.sacredheart.edu/pthms\\_exscifac](https://digitalcommons.sacredheart.edu/pthms_exscifac)



Part of the [Exercise Science Commons](#)

## Recommended Citation

Wagle, J., Carroll, K., Cunanan, A., Wetmore, A., Taber, C., Dewese, B.,...Stone, M. (2018). Preliminary investigation into the effect of ACTN3 and ACE polymorphisms on muscle and performance characteristics. *Journal of Strength and Conditioning Research*. doi: 10.1519/JSC.0000000000002809

This Peer-Reviewed Article is brought to you for free and open access by the Physical Therapy & Human Movement Science at DigitalCommons@SHU. It has been accepted for inclusion in Exercise Science Faculty Publications by an authorized administrator of DigitalCommons@SHU. For more information, please contact [ferribyp@sacredheart.edu](mailto:ferribyp@sacredheart.edu), [lysobeyb@sacredheart.edu](mailto:lysobeyb@sacredheart.edu).

---

**Authors**

John P. Wagle, Kevin M. Carroll, Aaron J. Cunanan, Alexander Wetmore, Christopher Taber, Brad H. Dewese, Kimitake Sato, and Charles A. Stuart

# PRELIMINARY INVESTIGATION INTO THE EFFECT OF *ACTN3* AND *ACE* POLYMORPHISMS ON MUSCLE AND PERFORMANCE CHARACTERISTICS

JOHN P. WAGLE,<sup>1</sup> KEVIN M. CARROLL,<sup>1</sup> AARON J. CUNANAN,<sup>1</sup> ALEXANDER WETMORE,<sup>1</sup> CHRISTOPHER B. TABER,<sup>2</sup> BRAD H. DEWEESE,<sup>1</sup> KIMITAKE SATO,<sup>1</sup> CHARLES A. STUART,<sup>3</sup> AND MICHAEL H. STONE<sup>1</sup>

<sup>1</sup>Department of Sport, Exercise, Recreation, and Kinesiology, Center of Excellence for Sport Science and Coach Education, East Tennessee State University, Johnson City, Tennessee; <sup>2</sup>Department of Physical Therapy and Human Movement Science, Sacred Heart University, Fairfield, Connecticut; and <sup>3</sup>Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson, City, Tennessee

## ABSTRACT

Wagle, JP, Carroll, KM, Cunanan, AJ, Wetmore, A, Taber, CB, DeWeese, BH, Sato, K, Stuart, CA, and Stone, MH. Preliminary investigation into the effect of *ACTN3* and *ACE* polymorphisms on muscle and performance characteristics. *J Strength Cond Res* XX(X): 000–000, 2018—The purpose of this investigation was to explore the phenotypic and performance outcomes associated with *ACTN3* and *ACE* polymorphisms. Ten trained men (age = 25.8 ± 3.0 years, height = 183.3 ± 4.1 cm, body mass = 92.3 ± 9.3 kg, and back squat to body mass ratio = 1.8 ± 0.3) participated. Blood samples were analyzed to determine *ACTN3* and *ACE* polymorphisms. Standing ultrasonography images of the vastus lateralis (VL) were collected to determine whole muscle cross-sectional area (CSA-M), and a percutaneous muscle biopsy of the VL was collected to determine type I-specific CSA (CSA-T1), type II-specific CSA (CSA-T2), and type II to type I CSA ratio (CSA-R). Isometric squats were performed on force platforms with data used to determine peak force (IPF), allometrically scaled peak force (IPFa), and rate of force development (RFD) at various timepoints. One repetition maximum back squats were performed, whereby allometrically scaled dynamic strength (DSa) was determined. Cohen's *d* effect sizes revealed *ACTN3* RR and *ACE* DD tended to result in greater CSA-M but differ in how they contribute to performance. *ACTN3* RR's influence seems to be in the type II fibers, altering maximal strength, and *ACE* DD may influence RFD capabilities through a favorable CSA-R. Although the findings of the current investigation are limited by the sample size, the findings demon-

strate the potential influence of *ACTN3* and *ACE* polymorphisms on isometric and dynamic strength testing. This study may serve as a framework to generate hypotheses regarding the effect of genetics on performance.

**KEY WORDS** fiber type, genetics, genotype, muscle size, strength, rate of force development

## INTRODUCTION

Athletic potential and performance outcomes are believed to be the result of a combination of several factors related to training and recovery strategies. Genotype, however, is likely the largest contributor to athletic potential and performance, with heritability estimated to be responsible for as much as 66% of performance (7). Human gene mapping has been especially insightful in the identification of candidate genes related to certain phenotypic characteristics. Two of the most extensively explored in athletics are the  $\alpha$ -actinin-3 (*ACTN3*) and angiotensin-converting enzyme (*ACE*) genes.

*ACTN3* encodes for the skeletal muscle  $\alpha$ -actinin-3, which is expressed predominantly in sarcomeres of fast-twitch, glycolytic muscle fibers (8,16). The expressed protein is believed to enhance structural integrity of the Z-line within these sarcomeres, consequently enhancing its force production capabilities. A polymorphism of the *ACTN3* gene that may influence the performance outcomes occurs at amino acid 577 (16). The replacement of arginine (R) with a stop codon (X) at that location within chromosome 11 creates the most notable gene variants pertaining to strength-power performance outcomes (6). The R allele and the RR polymorphism have well-established relationships to strength-power performance outcomes in a variety of populations, including soccer players (24), rowers (6), and sprinters (21). Furthermore, in *ACTN3* knockout mouse models, a decreased fiber-

Address correspondence to John P. Wagle, johnwagle9@gmail.com.

00(00)/1–7

*Journal of Strength and Conditioning Research*  
© 2018 National Strength and Conditioning Association

specific cross-sectional area (CSA) was observed in type II fibers with a concomitant reduction in strength (17).

*ACE* has several polymorphic sites, but of interest are the presence (insertion, I allele) or absence (deletion, D allele) of a 287-base pair (bp) Alu element fragment at intron 16. Fragment absence, the D allele, has been most associated with strength-power related phenotype (13), particularly in sprinters (20). This may be due to the increased localized *ACE* activity within the muscle observed in the presence of the D allele, ultimately leading to a greater conversion of angiotensin I to angiotensin II. A greater amount of angiotensin II has been associated with cell growth in endothelial, cardiac, and vascular smooth muscle cells. Because of the recently increasing evidence of localized renin-angiotensin systems within the muscle, it is possible that the D allele is associated with increased muscle growth, which would be advantageous for strength-power athletes (5).

The observed outcomes of certain *ACTN3* and *ACE* polymorphisms within the context of sport performance primarily address prevalence within certain athletic populations and the implications for talent identification. Few studies address the specific effects of polymorphisms on mechanistic strength-related characteristics (9,10). Although valuable, these investigations often focused on the untrained (3,9,10) or elderly (19). Therefore, there is a gap in the current literature exploring the potential effect of various polymorphisms of these 2 candidate genes have on mechanistic physical outputs—especially considering trained, strong subjects. Furthermore, to the authors' knowledge, no study has simultaneously examined the influence that *ACTN3* and *ACE* polymorphisms have on muscle characteristics. Therefore, the purpose of this investigation was to explore the phenotypic physiological and performance outcomes associated with the respective *ACTN3* and *ACE* polymorphisms in trained subjects. Specifically, the authors aimed to provide a rationale for further investigation of (a) the potential effect that *ACTN3* and *ACE* polymorphisms have on whole muscle and fiber-specific characteristics and (b) the effect that *ACTN3* and *ACE* polymorphisms have on isometric and dynamic performance capabilities.

## METHODS

### Experimental Approach to the Problem

To explore the phenotypic physiological and performance outcomes associated with *ACTN3* and *ACE* polymorphisms, subjects were asked to complete a testing series beginning with a whole blood draw, which would eventually be used for genotyping. Immediately thereafter, subjects completed standing ultrasonography measurements and a one-time subcutaneous muscle biopsy—both of the vastus lateralis (VL). After 48 hours of rest, subjects returned to complete isometric squat (ISQ) testing performed on dual force platforms to assess isometric strength and rate of force development (RFD) capabilities. Finally, subjects completed a 1

repetition maximum (1RM) back squat after another 48-hour rest period.

### Subjects

Ten well-trained men (mean  $\pm$  SD; age =  $25.8 \pm 3.0$  years, height =  $183.3 \pm 4.1$  cm, body mass =  $92.3 \pm 9.3$  kg, and back squat to body mass ratio =  $1.8 \pm 0.3$ ) volunteered for the current investigation. Subjects, most of whom were former athletes including Division I and professional status, were required to have spent at least the past year engaging in a strength training program that included back squats. Each subject's hydration status (urinary specific gravity) was determined using a refractometer (Atago, Tokyo, Japan) before any data collection to ensure that hydration status would not influence the results. All subjects read and signed a written informed consent form, and the procedures were approved by East Tennessee State University's Institutional Review Board.

### Procedures

**Genotyping.** A 10-ml blood sample was drawn into 2 separate 4-ml EDTA tubes (BD Vacutainer K2 EDTA; Franklin Labs, NJ, USA) by venipuncture from certified personnel. The whole blood samples were stored at  $-80^{\circ}\text{C}$  until subsequent analysis. Automated DNA extraction was performed using the manual processing protocol of the QIAamp DNA Blood Mini Kit (Qiagen, Crawley, United Kingdom). Real-time polymerase chain reaction (PCR) was performed to determine the genotype of the *ACTN3* and *ACE* polymorphisms in each subject, with reactions performed on 96-well microtiter plates. Each 50  $\mu\text{l}$  of reaction volume contained 25- $\mu\text{l}$  Platinum Superfi PCR Master Mix (ThermoFisher, Waltham, MA, USA), 10- $\mu\text{l}$  5X Superfi GC Enhancer (ThermoFisher, Waltham, MA, USA), 2.5  $\mu\text{l}$  of both the respective forward and reverse primers for *ACTN3* and *ACE*, and 12.5  $\mu\text{l}$  of subject DNA combined with nuclease-free water at a concentration of approximately  $250\text{ ng}\cdot\mu\text{l}^{-1}$ .

For *ACTN3*, the 290-bp fragment of exon 15 was amplified using the forward primer CTGTTGCCTGTGGTAAGTGGG and the reverse primer TGGTCACAGTATGCAGGAGGG. Polymerase chain reaction was performed for 35 cycles (30 seconds of denaturation at  $94^{\circ}\text{C}$ , 30 seconds of annealing at  $65^{\circ}\text{C}$ , and 60 seconds of extension at  $72^{\circ}\text{C}$ ), final extension at  $72^{\circ}\text{C}$  for 5 minutes, and held at  $4^{\circ}\text{C}$ . Amplified products were then electrophoresed on 0.5% agarose gel stained with ethidium bromide to confirm primer adherence. Samples were then purified using QIAquick PCR Purification Kit (Qiagen, Calgary, United Kingdom). After purification, *ACTN3* polymorphisms were determined using an automated DNA sequencer (CEQ 8000 Genetic Analysis System; Beckman Coulter, Indianapolis, IN, USA).

The *ACE* PCR amplification followed identical procedures of those used for *ACTN3* except for the substitution of specific primers for *ACE*—the forward primer CTGGAGACCACTCC-CATCCTTTCT and reverse primer GATGTGGCCATCA-CATTCGTCAGA. To determine polymorphism, amplified products were electrophoresed and visualized by using agarose

gels stained with ethidium bromide. The products were assessed for the presence of a 490 bp fragment (I allele), a 190 bp fragment (D allele), or both (I/D heterozygote) (Figure 1). Genotyping was performed in accordance with published genotyping and quality control recommendations including external control samples and internal controls of genotyping samples in duplicates (23,29).

**Standing Ultrasonography Measurement.** Standing ultrasonography measures began with the application of a water-soluble transmission gel to the measurement site and a 16-Hz probe oriented in the short-axis, perpendicular to the VL muscle, while not depressing the skin. Subjects were upright and bearing weight on the opposite leg, which was positioned on a 5-cm tall platform, unweighting the measured leg and creating an internal knee angle of  $160 \pm 10^\circ$  (30). Cross-sectional area (CSA-M) was obtained using a panoramic image sweep in the transverse plane perpendicular to the muscle (31). A straight-edge was placed along the skin to ensure that the probe remained along the previously established midline. Three images were obtained and saved for subsequent analysis using the software provided within the ultrasonography device.

**Muscle Biopsy Sampling and Processing.** Immediately after ultrasonography and blood draw procedures, all subjects received a one-time percutaneous biopsy. Biopsies of the superficial region of right VL at a depth of approximately 3 cm were obtained using the Bergström (2) technique and a 5-mm biopsy needle with suction with 1% lidocaine as a local anesthetic. A portion of the muscle tissue was immediately mounted on cork under a microscope to orient the specimen for transverse sectioning, frozen in a slurry of isopentane cooled by liquid nitrogen, and stored at  $-80^\circ\text{C}$  until subsequent processing. The samples were sectioned on a cryostat (Leica, Wetzlar, Germany) at a thickness of

14  $\mu\text{m}$  and affixed to a microscope slide in preparation for immunohistochemical analysis.

After sectioning and mounting, tissues were fixed with acetone at  $-20^\circ\text{C}$  for 2 sets of 5 minutes each. All samples were then blocked for 2 hours in a 10% normal goat serum. Sections were incubated overnight in monoclonal antibodies specific to myosin heavy chain (MYH) isoforms: MYH2 for type IIA fibers (IgG1, 1:100 dilution) and MYH7 for type I fibers (IgG2b, 1:200 dilution) (Developmental Studies Hybridoma Bank; University of Iowa, Iowa City, IA, USA). Finally, samples were then incubated for 2 hours using goat antimouse AlexaFluor 350 (IgG1) and AlexaFluor 555 (IgG2b), each at 1:200 dilution (Invitrogen, Carlsbad, CA, USA).

A series of photographs were taken of the slides at  $\times 10$  magnification using an Olympus BX41 microscope (Olympus America, Inc., Melville, NY) and imaged using an Olympus Q-Color3 camera (Olympus America, Inc., Melville, NY). Fibers were classified, counted, and sized using the ImageJ software (National Institute of Health, USA). Using the color composite feature within the software, fiber types were identified and sized objectively based on the color-specific staining intensity within each. Type I-specific CSA (CSA-T1), type II-specific CSA (CSA-T2), and type II to type I CSA ratio (CSA-R) were calculated from the collected data.

**Isometric Strength Assessment.** Subjects completed a standardized general warm-up sequence before beginning the isometric strength assessment. Isometric strength was assessed using the ISQ using an adapted protocol from McBride et al. (18). Subject bar heights were set such that an internal knee angle of  $100^\circ$  existed, which was assessed through goniometer (18). Data were collected using a dual force platform design ( $2 \times 91\text{ cm} \times 45.5\text{ cm}$  of force platforms; RoughDeck HP, Rice Lake, WI, USA) inside a custom-built apparatus with data sampled at 1,000 Hz.

Participants completed warm-up trials at 50 and 75% of their perceived maximal effort before performing a minimum of 2 maximal effort trials. If a countermovement of greater than 200 N was observed, or trials differed by more than 250 N, subjects were required to complete an additional trial (15). Participants were also instructed to push “as fast and hard as possible” and were strongly verbally encouraged during trials (18). A 3-minute seated rest interval was prescribed between each of the ISQ trials. LabVIEW (Version 7.1; National Instruments, Austin, TX, USA) was used for collecting and ForceDecks (Version 1.2.6464; NMP Technologies Ltd., London, United Kingdom) for processing kinetic data (4). Peak force (IPF), allometrically scaled peak force (IPFa), and RFD over 50 ms (RFD-50), 100 ms (RFD-100), and 200 ms (RFD-200) were calculated from the collected data.

**Dynamic Strength Assessment.** Dynamic strength was measured using a 1RM back squat. Dynamic strength testing was completed after ISQ and after 48 hours of rest to ensure that




Figure 1. ACE polymorphism results by subject.

subjects were adequately recovered. Before testing, each subject performed a general dynamic warm-up.

After the general warm-up, bar and safety bar heights in the squat rack were adjusted as needed to best accommodate each subject. Subjects warmed up with progressively heavier loads of 30, 50, 70, 80, and 90% of their self-reported 1RM for 5, 3, 2, 1, and 1 repetitions, respectively, before maximal attempts. Each subject attained their 1RM back squat by attempting progressively heavier loads until they could not complete a successful repetition. For a repetition to be considered successful, the subject's hip crease must have been below the patella at the bottom of the descent during the back squat and was verified by multiple certified strength and conditioning coaches. One repetition maximum back squat and allometrically scaled dynamic strength (DSa) were calculated from the collected data.

**Statistical Analyses**

Subjects were grouped by polymorphism for both *ACTN3* and *ACE* for analysis. Descriptive statistics including mean and *SD* were calculated. Within-subject reliability for each variable was assessed using intraclass correlation coefficients (ICCs) (12). Between-group Cohen's *d* effect sizes were calculated for each dependent variable to determine the magnitude and meaningfulness of performance differences across polymorphisms. Effect sizes were interpreted with magnitude thresholds of 0–0.2, 0.2–0.6, 0.6–1.2, 1.2–2.0, and 2.0 and above as trivial, small, moderate, large, and very large (11). Statistical analyses were performed using Microsoft Excel (Redmond, WA, USA).

**RESULTS**

All performance-dependent variables in the current investigation returned acceptable ICC values (11). The frequency of RR, RX, and XX *ACTN3* genotypes was 70% (*n* = 7), 30% (*n* = 3), and 0% (*n* = 0), respectively. The frequency of DD, ID, and II *ACE* genotypes was 30% (*n* = 3), 50% (*n* = 5), and 20% (*n* = 2), respectively (Figure 1).

A moderate between-group effect (*d* = 0.61) favored *ACTN3* RR compared with *ACTN3* RX for CSA-M. In addition, a small between-group effect favored *ACTN3* RR for CSA-T1 (*d* = 0.21), CSA-T2 (*d* = 0.42), and CSA-R (*d* = 0.58). Isometric and dynamic performance outcomes also favored *ACTN3* RR over *ACTN3* RX, yielding moderate between-group effect magnitudes for IPF (*d* = 0.73), IPFa (*d* = 0.94), RFD-200 (*d* = 0.64), and 1RM (*d* = 0.99), along with a large effect for DSa (*d* = 1.51) (Table 1).

A moderate between-group effect for CSA-M favored *ACE* DD compared with *ACE* ID (*d* = 0.67) and *ACE* ID over *ACE* II (*d* = 0.65), along with a large positive effect in *ACE* DD over *ACE* II (*d* = 1.37). A moderate unfavorable effect for CSA-T1 was observed in *ACE* ID compared with *ACE* DD (*d* = -0.83) and *ACE* II compared with *ACE* DD (*d* = -0.80)—meaning that CSA-T1 was smallest in *ACE* DD. Conversely, small effects were present favoring *ACE*

**TABLE 1.** Between-group Cohen's *d* effect size and the corresponding practical interpretation.\*

|                          | Muscle characteristics |                   |                  |                  |  | Performance characteristics |                  |                  |                  |                  |                  |                  |
|--------------------------|------------------------|-------------------|------------------|------------------|--|-----------------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                          | CSA-M                  | CSA-T1            | CSA-T2           | CSA-R            |  | IPF                         | IPFa             | RFD-50           | RFD-100          | RFD-200          | 1RM              | DSa              |
| <i>ACTN3</i><br>RR to RX | 0.61<br>Moderate       | 0.21<br>Small     | 0.42<br>Small    | 0.15<br>Trivial  |  | 0.73<br>Moderate            | 0.94<br>Moderate | 0.43<br>Small    | 0.46<br>Small    | 0.64<br>Moderate | 0.99<br>Moderate | 1.51<br>Large    |
| <i>ACE</i><br>DD to ID   | 0.67<br>Moderate       | -0.83<br>Large    | -0.14<br>Trivial | 0.48<br>Small    |  | 0.70<br>Moderate            | 0.58<br>Small    | 0.33<br>Small    | 0.33<br>Small    | 0.50<br>Small    | 1.14<br>Moderate | 1.06<br>Moderate |
| ID to II                 | 0.65<br>Moderate       | 0.35<br>Small     | 0.11<br>Trivial  | 0.33<br>Small    |  | -0.25<br>Small              | -0.37<br>Small   | 0.60<br>Moderate | 0.69<br>Moderate | 0.23<br>Small    | 0.01<br>Trivial  | -0.19<br>Trivial |
| DD to II                 | 1.37<br>Large          | -0.80<br>Moderate | 0.00<br>Trivial  | 0.79<br>Moderate |  | 0.38<br>Small               | 0.15<br>Trivial  | 0.54<br>Small    | 0.66<br>Moderate | 0.57<br>Small    | 0.93<br>Moderate | 0.62<br>Moderate |

\*CSA-M = whole muscle cross-sectional area; CSA-T1 = type I fiber cross-sectional area; CSA-T2 = type II fiber cross-sectional area; CSA-R = type II to type I cross-sectional area ratio; IPF = peak force; IPFa = allometrically scaled peak force; RFD-50 = rate of force development at 50 ms; RFD-100 = rate of force development at 100 ms; RFD-200 = rate of force development at 200 ms; 1RM = 1 repetition maximum back squat; DSa = allometrically scaled dynamic strength.

ID over *ACE* II ( $d = 0.35$ ) in CSA-T1. *ACE* DD had a moderate effect difference over *ACE* II in CSA-R ( $d = 0.88$ ). Furthermore, large favorable effects were present comparing *ACE* DD with *ACE* ID in CSA-R. ( $d = 1.42$ ). Trivial effects were observed comparing all *ACE* polymorphisms for CSA-T2 (Table 1). Considering *ACE* DD with respect to *ACE* ID, a moderate favorable effect was observed for IPF ( $d = 0.70$ ), 1RM ( $d = 1.14$ ), and DSa ( $d = 1.06$ ). *ACE* ID had a moderate favorable effect for RFD-100 ( $d = 0.69$ ) relative to *ACE* II. Finally, moderate effects favored *ACE* DD over *ACE* II in RFD-100 ( $d = 0.66$ ), 1RM ( $d = 0.93$ ), and DSa ( $d = 0.62$ ).

## DISCUSSION

The purpose of this investigation was to explore the potential physiological and performance outcomes associated with *ACTN3* and *ACE* polymorphisms. Specifically, the authors aimed to examine (a) the potential effect that *ACTN3* and *ACE* polymorphisms have on muscle characteristics including whole muscle, fiber-specific morphology and fiber-specific CSA distribution and (b) the effect that *ACTN3* and *ACE* polymorphisms have on isometric and dynamic performance capabilities. The main results of this investigation have shown that subjects possessing the *ACTN3* RR polymorphism had larger whole muscle and fiber-specific CSA as well as a greater CSA-R compared with *ACTN3* RX. Furthermore, our results indicate that individuals with the *ACTN3* RR variant were stronger under both isometric and dynamic conditions and may possess greater RFD capabilities. Although *ACE* DD had the largest whole muscle CSA, a moderate between-group effect favored *ACE* ID and *ACE* II variants for CSA-T1. However, no meaningful effects were observed for CSA-T2.

Whole muscle CSA, often used as an indicator of force production capabilities (26), is affected by both inherited (i.e., candidate gene polymorphism) and environmental factors (i.e., training and nutrition). Because of the  $\alpha$ -actinin-3 protein's role as an actin anchor within the Z-line of fast muscle and *ACE*'s role in the synthesis of angiotensin II and cell growth, both provide mechanistic rationale for a larger muscle phenotype. The *ACTN3* R allele has been associated with larger whole muscle size in previous literature (32), which agrees with the findings of the current investigation. However, Zempo et al. (32) compared the presence of the R allele (i.e., *ACTN3* RR and RX) with *ACTN3* XX. In the current investigation, no X allele homozygotes were present, but the findings do reveal the potential that R allele homozygotes (*ACTN3* RR) possess a greater whole muscle size in comparison with heterozygotes (*ACTN3* RX).

The *ACE* DD polymorphism presents a less clear mechanistic rationale as it relates to muscle size (10), although previous literature has indicated that the D allele is associated with greater changes in muscle CSA after resistance training (23). It has been postulated that, because there is a high prevalence of *ACE* within the muscle, that the generation of angiotensin II (a potent growth regulator in car-

diac and smooth muscle) provides a link to larger muscle sizes. The presence of the *ACE* II genotype has been associated with high-level endurance performance (20), which typically favors athletes with lesser muscle mass than strength-power athletes (1). In addition, previous longitudinal research has suggested a preference for *ACE* DD and *ACE* ID variants for the gaining of muscle mass over *ACE* II (5). Indeed, the results of the current cross-sectional investigation indicated that muscle mass was from greatest-to-least: *ACE* DD > *ACE* ID > *ACE* II. Although training, nutrition, and other factors may ultimately determine the muscle size as an adult, the presence of one or both polymorphisms may provide for a greater potential for muscle hypertrophy, and therefore a greater force production capability.

Strength potential is also closely related to the composition of the muscle. This includes fiber-type specific CSA and the CSA-R. The current investigation provided interesting considerations in this regard, demonstrating the potential that *ACTN3* RR may have a small effect on both CSA-T1 and CSA-T2 compared with *ACTN3* RX. The *ACTN3* RR genotype has been linked to elite strength-power performance in track and field (22,25). Therefore, the findings of the current investigation lend support for previous findings, especially considering *ACTN3*'s function within fast, glycolytic fibers. Interestingly, the *ACE* DD genotype was associated with a moderate decrease in CSA-T1 compared with the other genotypes and no effect in CSA-T2. However, there was a small between-group effect favoring *ACE* DD over *ACE* ID and a moderate effect supporting *ACE* DD over *ACE* II, which creates a potentially favorable scenario for force production abilities. Considering the potential combination of *ACTN3* RR (i.e., larger CSA-T2) and *ACE* DD (i.e., smaller CSA-T1), there may be a situation where the CSA-R may be maximized. Greater CSA-R may minimize the drag effect that T1 fibers have on T2 fibers during whole muscle contraction, potentially increasing the maximum contraction velocity (14,28). A higher contraction velocity would be beneficial to performances in strength-power events, particularly in sprinting and jumping, which involve high RFDs and dynamic strength.

The *ACTN3* RR and *ACE* DD genotypes were simultaneously present in 2 subjects in the current investigation. Although there are technical limitations of only having 2 subjects with these genotypes simultaneously, it is interesting to note that these subjects yielded among the greatest scores on isometric and dynamic strength as well as RFD. More specifically, one of the subjects had the highest CSA-M, greatest CSA-R, and ranked first in each performance measure collected including absolute and relative measures of strength performance and RFD at all considered timepoints. The other subject possessing both genotypes had the second highest CSA-M, was second in 1RM, third in IPF and DSa, and fourth in IPFa. The RFD capabilities of the second subject increased in rank as the timepoint expanded, moving from seventh in RFD-50 up to fourth in RFD-200 among

all subjects. The lower ranking in the early RFD timepoints may be partly due to this subject's seventh-ranked CSA-R, which has been previously connected to RFD capabilities (28). This variability in RFD may indicate the importance of training, as the subjects had different athletic backgrounds. It may also suggest that there are other genes and their respective polymorphisms that must be taken into consideration that more drastically influence RFD capabilities than *ACTN3* and *ACE*. This list may contain more than 40 candidate genes (27) including, but not limited to *MCT1* (monocarboxylate transport 1), *MYLK* (myosin light chain kinase), *COL1-A1* (collagen  $\alpha$ -1 chain type I), insulin-like growth factor-related genes, or myostatin-related genes (27). As demonstrated, the factors influencing strength performance are robust and comprise bioenergetic, structural, and regulatory aspects.

Although the findings of the current investigation are limited by the sample size, it is the first of the authors' knowledge to investigate the potential influence of *ACTN3* and *ACE* polymorphisms on isometric and dynamic strength testing. This research has the potential to act as a framework for the generation of future hypotheses within strength and conditioning research as it relates to the influence of genetics. The current investigation suggests that the *ACTN3* RR and *ACE* DD tend to result in greater whole muscle size but differ in how they contribute to performance capacities. While *ACTN3* RR's influence seems to be in the T2 fibers and therefore alters gross isometric and strength performance, *ACE* DD seems to influence RFD capabilities through creating a favorable CSA-R. Future investigations should continue to explore the individual and combined effects of these 2 genotypes as well as the inclusion of other heritable characteristics and their relative contributions to performance potential and outcomes.

### PRACTICAL APPLICATIONS

The findings of the current investigation provide unique considerations for talent identification of strength-power athletes. Although previous investigations have explored the general physical qualities associated with these 2 candidate genes and their respective polymorphisms, the current investigation is the first to provide specific effect magnitudes on mechanistic strength qualities, albeit with a limited sample size. This may be valuable for organizations and governing bodies with long-term athlete development models that guide younger athletes toward certain sports in which they have a higher likelihood for success.

### ACKNOWLEDGMENTS

The authors thank Dr. Michelle Duffourc and Mary Howell for their contributions in experimental design and execution of biological sample analysis. The authors thank Dr. Matt L. Sams, Joseph A. Walters, and Garrett E. Bingham for their contributions in data collection and processing.

### REFERENCES

1. Bassett, DR Jr and Howley, ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Med Sci Sports Exerc* 32: 70, 2000.
2. Bergström, J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. *Scand J Clin Lab Invest* 35: 609–616, 1975.
3. Broos, S, Van Leemputte, M, Deldicque, L, and Thomis, MA. History-dependent force, angular velocity and muscular endurance in *ACTN3* genotypes. *Eur J Appl Physiol* 115: 1637–1643, 2015.
4. Carroll, KM, Wagle, JP, Sato, K, DeWeese, BH, Mizuguchi, S, and Stone, MH. Reliability of a commercially available and algorithm-based kinetic analysis software compared to manual-based software. *Sports Biomech* 26: 1–9, 2017.
5. Charbonneau, DE, Hanson, ED, Ludlow, AT, Delmonico, MJ, Hurley, BF, and Roth, SM. *ACE* genotype and the muscle hypertrophic and strength responses to strength training. *Med Sci Sports Exerc* 40: 677, 2008.
6. Cieszczyk, P, Sawczuk, M, Maciejewska-Karłowska, A, and Ficek, K. *ACTN3* R577X polymorphism in top-level Polish rowers. *J Exerc Sci Fitness* 10: 12–15, 2012.
7. De Moor, MH, Spector, TD, Cherkas, LF, Falchi, M, Hottenga, JJ, Boomsma, DI, et al. Genome-wide linkage scan for athlete status in 700 British female DZ twin pairs. *Twin Res Hum Genet* 10: 812–820, 2007.
8. Durmic, TS, Zdravkovic, MD, Djelic, MN, Gavrilovic, TD, Saranovic, SAD, Plavsic, JN, et al. Polymorphisms in *ACE* and *ACTN3* genes and blood pressure response to acute exercise in elite male athletes from Serbia. *Tohoku J Exp Med* 243: 311–320, 2017.
9. Erskine, RM, Williams, AG, Jones, DA, Stewart, CE, and Degens, H. The individual and combined influence of *ACE* and *ACTN3* genotypes on muscle phenotypes before and after strength training. *Scand J Med Sci Sports* 24: 642–648, 2014.
10. Folland, J, Leach, B, Little, T, Hawker, K, Myerson, S, Montgomery, H, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. *Exp Physiol* 85: 575–579, 2000.
11. Hopkins, W, Marshall, S, Batterham, A, and Hanin, J. Progressive statistics for studies in sports medicine and exercise science. *Med Sci Sports Exerc* 41: 3, 2009.
12. Hopkins, WG. Spreadsheets for analysis of validity and reliability. *Sports Science* 21: 36–44, 2017.
13. Jones, A, Montgomery, HE, and Woods, DR. Human performance: A role for the *ACE* genotype? *Exerc Sport Sci Rev* 30: 184–190, 2002.
14. Komi, PV. Physiological and biomechanical correlates of muscle function: Effects of muscle structure and stretch-shortening cycle on force and speed. *Exerc Sport Sci Rev* 12: 81–122, 1984.
15. Kraska, JM, Ramsey, MW, Haff, GG, Fethke, N, Sands, WA, Stone, ME, et al. Relationship between strength characteristics and unweighted and weighted vertical jump height. *Int J Sports Physiol Perform* 4: 461–473, 2009.
16. Ma, F, Yang, Y, Li, X, Zhou, F, Gao, C, Li, M, et al. The association of sport performance with *ACE* and *ACTN3* genetic polymorphisms: A systematic review and meta-analysis. *PLoS One* 8: e54685, 2013.
17. MacArthur, DG, Seto, JT, Raftery, JM, Quinlan, KG, Huttley, GA, Hook, JW, et al. Loss of *ACTN3* gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. *Nat Genet* 39: 1261, 2007.
18. McBride, JM, Cormie, P, and Deane, R. Isometric squat force output and muscle activity in stable and unstable conditions. *J Strength Cond Res* 20: 915–918, 2006.
19. Min, SK, Lim, ST, and Kim, CS. Association of *ACTN3* polymorphisms with BMD, and physical fitness of elderly women. *J Phys Ther Sci* 28: 2731–2736, 2016.



20. Myerson, S, Hemingway, H, Budget, R, Martin, J, Humphries, S, and Montgomery, H. Human angiotensin I-converting enzyme gene and endurance performance. *J Appl Physiol* 87: 1313–1316, 1999.
21. Niemi, AK and Majamaa, K. Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. *Eur J Hum Genet* 13: 965, 2005.
22. Papadimitriou, I, Papadopoulos, C, Kouvatzi, A, and Triantaphyllidis, C. The ACTN3 gene in elite Greek track and field athletes. *Int J Sports Med* 29: 352–355, 2008.
23. Pescatello, LS, Kostek, MA, Gordish-Dressman, H, Thompson, PD, Seip, RL, Price, TB, et al. ACE ID genotype and the muscle strength and size response to unilateral resistance training. *Med Sci Sports Exerc* 38: 1074–1081, 2006.
24. Pimenta, EM, Coelho, DB, Veneroso, CE, Coelho, EJB, Cruz, IR, Morandi, RF, et al. Effect of ACTN3 gene on strength and endurance in soccer players. *J Strength Cond Res* 27: 3286–3292, 2013.
25. Roth, SM, Walsh, S, Liu, D, Metter, EJ, Ferrucci, L, and Hurley, BF. The ACTN3 R577X nonsense allele is under-represented in elite-level strength athletes. *Eur J Hum Genet* 16: 391, 2008.
26. Seynnes, OR, de Boer, M, and Narici, MV. Early skeletal muscle hypertrophy and architectural changes in response to high-intensity resistance training. *J Appl Physiol* 102: 368–373, 2007.
27. Thomis, MA and Aerssens, J. Genetic variation in human muscle strength—opportunities for therapeutic interventions? *Curr Opin Pharmacol* 12: 355–362, 2012.
28. Thorstensson, A, Grimby, G, and Karlsson, J. Force-velocity relations and fiber composition in human knee extensor muscles. *J Appl Physiol* 40: 12–16, 1976.
29. Vigano, A, Trutschnigg, B, Kilgour, RD, Hamel, N, Hornby, L, Lucar, E, et al. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. *Clin Cancer Res* 15: 2442–2447, 2009.
30. Wagle, JP, Carroll, KM, Cunanan, AJ, Taber, CB, Wetmore, A, Bingham, GE, et al. Comparison of the relationship between lying and standing ultrasonography measures of muscle morphology with isometric and dynamic force production capabilities. *Sports* 5: 88, 2017.
31. Wells, AJ, Fukuda, DH, Hoffman, JR, Gonzalez, AM, Jajtner, AR, Townsend, JR, et al. Vastus Lateralis exhibits non-homogenous adaptation to resistance training. *Muscle Nerve* 50: 785–793, 2014.
32. Zempo, H, Tanabe, K, Murakami, H, Iemitsu, M, Maeda, S, and Kuno, S. ACTN3 polymorphism affects thigh muscle area. *Int J Sports Med* 31: 138–142, 2010.